Hygiene and Public Health Unit, Laboratory of Health Care Services and Health Promotion Evaluation, Department of Cardiologic, Vascular and Thoracic Sciences, and Public Health, University of Padua, Via Loredan, 18, 35131, Padua, Italy.
Pathology and Cytopathology Unit, Department of Medicine - DIMED, University of Padua, Padua, Italy.
BMC Geriatr. 2024 Mar 6;24(1):232. doi: 10.1186/s12877-024-04806-8.
In industrialized countries, the aging population is steadily rising. The incidence of cutaneous malignant melanoma (CMM) is highest in old people. This study focuses on the clinicopathological profile of CMM and indicators of diagnostic-therapeutic performance in older patients.
This retrospective population-based cohort study included 1,368 incident CMM, as recorded in 2017 by the Regional Veneto Cancer Registry (Northeast Italy). Older subjects were defined as ≥ 80, old as 65-79, and adults as < 65 years of age. The strength of association between pairs of variables was tested by Cramer's-V. Using age groups as the dependent variable, ordered logistic regression was fitted using the clinicopathological CMM profiles as covariates. In each of the three age-groups, the indicators of clinical performance were computed using the Clopper-Pearson exact method.
Compared to patients aged younger than 80 years (1,187), CMM in older patients (181; 13.2%) featured different CMM topography, a higher prevalence of ulcers (43.3% versus 12.7%; p < 0.001), a higher Breslow index (p < 0.001), a lower prevalence of tumor-infiltrating lymphocytes (64.4% versus 76.5%, p < 0.01), and a more advanced pTNM stage at clinical presentation (p < 0.001). Elderly patients with a positive sentinel-lymph node less frequently underwent sentinel- lymph node biopsy and lymphadenectomy (60.0% versus 94.2%, and 44.4% versus 85.5%, respectively; p < 0.001).
In older CMM patients, the clinicopathological presentation of CMM shows a distinctive profile. The present results provide critical information to optimize secondary prevention strategies and refine diagnostic-therapeutic procedures tailored to older patients.
在工业化国家,人口老龄化稳步上升。皮肤恶性黑色素瘤(CMM)的发病率在老年人中最高。本研究重点关注 CMM 的临床病理特征以及老年患者的诊断-治疗性能指标。
本回顾性基于人群的队列研究纳入了 2017 年由威尼托地区癌症登记处(意大利东北部)记录的 1368 例 CMM 新发病例。老年患者定义为≥80 岁,老年人为 65-79 岁,成年人<65 岁。使用 Cramer's-V 检验检验两组变量之间的关联强度。使用年龄组作为因变量,使用临床病理 CMM 特征作为协变量拟合有序逻辑回归。在每个年龄组中,使用 Clopper-Pearson 精确法计算临床性能指标。
与年龄小于 80 岁的患者(1187 例)相比,年龄较大患者(181 例;13.2%)的 CMM 具有不同的 CMM topography、更高的溃疡发生率(43.3%比 12.7%;p<0.001)、更高的 Breslow 指数(p<0.001)、更低的肿瘤浸润淋巴细胞发生率(64.4%比 76.5%,p<0.01),以及更晚期的 pTNM 分期(p<0.001)。有阳性前哨淋巴结的老年患者较少进行前哨淋巴结活检和淋巴结切除术(60.0%比 94.2%,44.4%比 85.5%;p<0.001)。
在老年 CMM 患者中,CMM 的临床病理表现具有独特的特征。本研究结果为优化二级预防策略和完善针对老年患者的诊断-治疗程序提供了重要信息。